However, a substantial proportion of breast cancer patients do not respond to this drug, Targeting Her-2 alone by trastuzumab may, under some conditions, not be sufficient to halt the rapid growth of tumor cells that also express high levels of Lin28A. This evidence concerns the gene ERBB2 and breast carcinoma.